By Elaine Rigoli
Tampa, Fla., March 21 - EKOS Corp. announced Tuesday it has secured $26 million in series C financing enabling the formation of a commercial sales and marketing team to support the company's ultrasound-assisted, fluid infusion catheters.
The investment was led by Ascension Health Ventures, with additional support from new investors Oakwood Medical Investors and Trellis Health Ventures as well as previous investors CID Equity Capital, EGS Private Healthcare Investors, MedVenture Associates, Mitsui & Co. Venture Partners, Morgan Stanley Venture Partners and NGN Capital, according to a news release.
The company's lysus peripheral infusion system and micro-infusion catheter are cleared for the delivery of therapeutic agents. The micro-infusion catheter is also cleared for the administration of contrast media into the brain.
"The corporate growth made possible by this round of financing is important not only for EKOS, but also for the significant populations that suffer with peripheral vascular diseases or are at risk for ischemic stroke," said Peter Rule, chairman and chief executive officer, in a statement.
EKOS, based in Bothell, Wash., provides ultrasound-assisted, fluid infusion catheters for diagnosis and therapy.
| Issuer: | EKOS Corp.
|
| Issue: | Series C financing
|
| Amount: | $26 million
|
| Investors: | Ascension Health Ventures, Oakwood Medical Investors, Trellis Health Ventures, CID Equity Capital, EGS Private Healthcare Investors, MedVenture Associates, Mitsui & Co. Venture Partners, Morgan Stanley Venture Partners, NGN Capital
|
| Announcement date: | March 21
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
